Uncategorized
What is it like to live with chronic low back pain? A patient’s perspective
What is it like to live with chronic Low Back Pain (cLBP)? Patient Jesper Christensen from Denmark discusses his experience.
A Better Way to Treat Vertebrogenic Lumbar Back Pain
by Duncan McHale, Chief Medical Officer, Persica Pharmaceuticals Despite advances in imaging techniques chronic Low Back Pain is generally treated as a single condition with 80% of cases being classified as non-specific. Patients are grouped together and offered a similar sequence of options: exercise and physiotherapy, analgesics, and then – for those who do not respond – escalating interventions that
Persica Pharmaceuticals publishes new analysis of assay sensitivity in disc microbiology studies, reinforcing the potential for PP353 in vertebrogenic Lumbar Back Pain
Publication strengthens the scientific rationale for PP353 as a precisely targeted, non-opioid treatment for patients with vertebrogenic Lumbar Back Pain Manuscript submitted to the European Spine Journal and is available from their preprint server[1] London, UK, 11 September 2026 – Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP),
Persica Pharmaceuticals publishes new analyses of antibiotic exposure-response, reinforcing the scientific case for PP353 in vertebrogenic Lumbar Back Pain
The publication builds on Phase 1b PP353 data published in The Lancet’s eClinicalMedicine, further supporting the rationale for a targeted, non-opioid approach to vertebrogenic Lumbar Back Pain Manuscript has been submitted to the European Spine Journal and is available from their preprint server[1] London, UK, 04 September – Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted,
Persica Pharmaceuticals presents new analyses of microbiology assay sensitivity and intradiscal antibiotic exposure response in chronic Low Back Pain at ASPN 2026 Annual Conference
Poster presentation builds on Phase 1b PP353 data published in The Lancet’s eClinicalMedicine, reinforcing the rationale for a targeted, non-opioid approach to chronic Low Back Pain with Modic changes London, UK, 24 July 2026 – Persica Pharmaceuticals Limited (Persica), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), last week presented a new
Abstract award at American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
We are pleased to announce that Dr. Joshua Hirsch has been honored with a Top Abstract Award at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting for his presentation of Phase 1b data from Persica’s groundbreaking Modic Trial. Dr. Hirsch is a distinguished neurointerventionalist and Professor at Harvard Medical School. He serves as a Board Member of
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
New senior executives bring significant biopharma experience as Persica moves to next phase of its development London, UK, 23 March 2026 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has appointed Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer,
Persica Pharmaceutical’s PP353 Phase 1b Data Selected for Oral Presentation at the American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting
ASIPP presentation follows publication of positive data from PP353 Phase 1b Modic Trial in The Lancet’s eClinicalMedicine London, UK, 19 March 2026 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been selected to give an oral presentation at the American Society of Interventional
Positive Clinical Data for PP353 Published in The Lancet’s eClinicalMedicine
Persica Pharmaceuticals’ Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet’s eClinicalMedicine First publication of clinical efficacy data for PP353, in development for chronic Low Back Pain Trial demonstrated that PP353 delivers clinically meaningful and durable reduction in pain and disability in patients with chronic Low Back Pain and Modic Type 1 changes PP353
Talking non-opioid pain therapies with the FT
In November 2025, our CEO Steve Ruston participated in a fireside chat with FT US Pharmaceutical Correspondent Patrick Temple-West, discussing how the pharmaceutical industry is tackling chronic pain and the growing demand for non-addictive therapies, including the potential of one-off treatments like PP353 for chronic Low Back Pain associated with Modic changes. I recently had the opportunity to speak